Detection of the PAX8-PPARγ fusion oncogene in both follicular thyroid carcinomas and adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 1, 2003, Pages 354-357

  Cheung, Linda ^a   Messina, Marinella ^a   Gill, Anthony ^a   Clarkson, Adele ^a   Learoyd, Diana ^a   Delbridge, Leigh ^a   Wentworth, John ^a   Philips, Jeanette ^a   Clifton Bligh, Roderick ^a   Robinson, Bruce G ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; ONCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; DNA-BINDING PROTEINS; GENE EXPRESSION; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEAR PROTEINS; ONCOGENES; PAIRED BOX TRANSCRIPTION FACTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID NEOPLASMS; TISSUE DISTRIBUTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 0037238701     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021020     Document Type: Article

References (35)

1. Cap J, Ryska A, Rehorkova P, Hovorkova E, Kerekes Z, Pohnetalova D 1999 Sensitivity and specificity of the fine needle aspiration biopsy of the thyroid: clinical point of view. Clin Endocrinol (Oxf) 51:509-515
2. Haugen BR, Woodmansee WW, McDermott MT 2002 Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol (Oxf) 56:281-290
3. Tuttle RM, Lemar H, Burch HB 1998 Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. Thyroid 8:377-383
4. Saggiorato E, Cappia S, De Giuli P, Mussa A, Pancani G, Caraci P, Angeli A, Orlandi F 2001 Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 86:5152-158
5. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A 1998 Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58:3015-3020
6. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A 1999 Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 17:3494-3502
7. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T 1999 Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85:2475-2484
8. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O 2001 Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644-1650
9. De Micco C, Vassko V, Henry JF 1999 The value of thyroid peroxidase immunohistochemistry for preoperative fine-needle aspiration diagnosis of the follicular variant of papillary thyroid cancer. Surgery 126:1200-1204
10. De Micco C, Ruf J, Chrestian MA, Gros N, Henry JF, Carayon P 1991 Immunohistochemical study of thyroid peroxidase in normal, hyperplastic, and neoplastic human thyroid tissues. Cancer 67:3036-3041
11. Tanaka T, Umeki K, Yamamoto I, Sugiyama S, Noguchi S, Ohtaki S 1996 Immunohistochemical loss of thyroid peroxidase in papillary thyroid carcinoma: strong suppression of peroxidase gene expression. J Pathol 179:89-94
12. Watanabe K, Koizumi N, Ozaki O, Futaesaku Y, Hosoya T 1993 Immunohistochemical studies on thyroid peroxidase and thyroglobulin in 13 human thyroid tumors and 7 Graves' goiters. Endocr J 40:683-690
13. Umbricht CB, Saji M, Westra WH, Udelsman R, Zeiger MA, Sukumar S 1997 Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res 57:2144-2147
14. Yashima K, Vuitch F, Gazdar AF, Fahey III TJ 1997 Telomerase activity in benign and malignant thyroid diseases. Surgery 122:1141-1146
15. Lo CY, Lam KY, Chan KT, Luk JM 1999 Telomerase activity in thyroid malignancy. Thyroid 9:1215-1220
16. Haugen BR, Nawaz S, Markham N, Hashizumi T, Shroyer AL, Werness B, Shroyer KR 1997 Telomerase activity in benign and malignant thyroid tumors. Thyroid 7:337-342
17. Gerasimov G, Bronstein M, Troshina K, Alexandrova G, Dedov I, Jennings T, Kallakury BV, Izquierdo R, Boguniewicz A, Figge H 1995 Nuclear p53 immunoreactivity in papillary thyroid cancers is associated with two established indicators of poor prognosis. Exp Mol Pathol 62:52-62
18. Nishida T, Nakao K, Hamaji M, Nakahara MA, Tsujimoto M 1996 Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Surgery 119:568-575
19. Godballe C, Asschenfeldt P, Jorgensen KE, Bastholt L, Clausen PP, Hansen TP, Hansen O, Bentzen SM 1998 Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis. Laryngoscope 108:243-249
20. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA 2000 PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 289:1357-1360
21. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM 1996 The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668
22. Brown D, Kogan S, Lagasse E, Welssman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM 1997 A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:2551-2556
23. Hedinger CE WE, Sobin LH, eds. 1988 World Health Organization international histological classification of tumours: histological typing of thyroid tumours, 2nd Ed. Heidelberg: Springer-Verlag
24. Rosai J CM, Delellis RA 1992 Atlas of tumor pathology: tumours of the thyroid gland. Washington DC: Armed Forces Institute of Pathology
25. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V 2002 Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-3952
26. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE 1016 PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016-1023
27. Masood S, Auguste LJ, Westerband A, Belluco C, Valderama E, Attie J 1993 Differential oncogenic expression in thyroid follicular and Hurthle cell carcinomas. Am J Surg 166:366-368
28. Zedenius J, Wallin G, Svensson A, Grimelius L, Hoog A, Lundell G, Backdahl M, Larsson C 1995 Allelotyping of follicular thyroid tumors. Hum Gen 96:27-32
29. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, Borresen AL, Auer G 1996 Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. Thyroid 6:1-9
30. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M 2002 Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 160:1857-1865
31. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T 2001 Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86:2170-2177
32. Poleev A, Wendler F, Fickenscher H, Zannini MS, Yaginuma K, Abbott C, Plachov D 1995 Distinct functional properties of three human paired-box-protein, PAX8, isoforms generated by alternative splicing in thyroid, kidney and Wilms' tumors. Eur J Biochem 228:899-911
33. Kozmik Z, Kurzbauer R, Dorfler P, Busslinger M 1993 Alternative splicing of Pax-8 gene transcripts is developmentally regulated and generates isoforms with different transactivation properties. Mol Cell Biol 13:6024-6035
34. Pandolfi PP 2001 Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 48:S17-S19
35. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Lazar MA, Minucci S, Pelicci PG 1998 Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815-818